Parkinson’s disease affects over 10 million people worldwide, causing motor slowness, tremors and loss of coordination. Traditional treatments such as levodopa and deep brain stimulation (DBS) have limitations. A new study published in Nature uncovers a higher‑order brain network, the SCAN , whose abnormal strengthening offers a precise therapeutic target. Key Developments Researchers employed PFM to identify three consistent “dot” zones across the motor cortex, later named SCAN. Analysis of 863 Parkinson’s patients showed SCAN’s over‑connectivity with the basal ganglia and thalamus, a pattern absent in amyotrophic lateral sclerosis (ALS) patients. A pilot trial with 18 participants applied TMS to SCAN regions; compared with control stimulation of effector zones, the SCAN‑targeted group showed marked reduction in tremor, rigidity, bradykinesia and instability within two weeks. Experts suggest future non‑invasive and minimally invasive neuromodulatory therapies could be personalized using PFM‑guided SCAN targeting. Important Facts Traditional motor‑effector mapping (Penfield map) lacks the resolution to explain coordination deficits in Parkinson’s. PFM replaces population‑averaged imaging with individual‑specific maps, akin to moving from a cartoon face to a real portrait. SCAN integrates motor execution with planning and attention, bridging primary motor cortex and higher‑order cognitive areas. Over‑connectivity of SCAN serves as a potential biomarker for disease severity and treatment response. While promising, SCAN is not yet featured in standard neuro‑anatomical atlases. UPSC Relevance The discovery underscores the importance of interdisciplinary research—combining neuroscience, imaging technology and clinical trials—to address public health challenges. Aspirants should note the link between neuro‑degenerative disorders and health policy, especially in the context of ageing populations, healthcare infrastructure, and the need for affordable, scalable treatments (GS4: Health). Understanding concepts such as Parkinson’s disease and emerging therapeutic modalities can aid in answering ethics, governance and health‑system questions in the UPSC mains. Way Forward Further large‑scale, multi‑center trials are required to validate SCAN‑targeted TMS and to compare its efficacy against DBS and pharmacotherapy. Integration of PFM into routine neuro‑imaging could enable personalized treatment plans, reducing reliance on invasive procedures. Policymakers should facilitate funding for translational research, streamline regulatory pathways for non‑invasive neuromodulation, and update medical curricula to incorporate new network‑level biomarkers.